Leuphasyl vs Syn-Ake
These peptides target expression lines through entirely different mechanisms—Leuphasyl activates enkephalin receptors to reduce upstream calcium signalling, while Syn-Ake blocks post-synaptic nicotinic receptors to prevent muscle activation. Together they form a powerful dual-pathway approach.
Last updated: 2026-02-04
Leuphasyl and Syn-Ake represent two of the most mechanistically distinct neuromuscular peptides available—one working through the enkephalin (opioid receptor) pathway, the other through nicotinic acetylcholine receptor antagonism. Understanding their differences reveals why they're ideal partners in multi-peptide anti-ageing protocols.
**Leuphasyl (Pentapeptide-18)** was developed by Lipotec as an enhancer peptide, designed to complement SNARE-targeting peptides like Argireline. It works UPSTREAM in the neuromuscular cascade by activating δ-opioid (enkephalin) receptors, which reduces calcium channel activity and subsequently decreases neurotransmitter release probability.
**Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate)** was developed by Pentapharm as a waglerin-1 mimetic. It works at the POST-SYNAPTIC side of the neuromuscular junction, competitively blocking nicotinic acetylcholine receptors on muscle cells to prevent signal reception.
This comparison explores how these two peptides—positioned at opposite ends of the neuromuscular signalling cascade—create genuine synergy when combined, addressing expression lines through multiple independent pathways.
Quick Comparison Table
| Category | Leuphasyl | Syn-Ake |
|---|---|---|
| Mechanism | Enkephalin receptor activation | Nicotinic receptor antagonism |
| Target Location | Pre-synaptic nerve terminal | Post-synaptic muscle membrane |
| Pathway Position | Upstream (reduces trigger signal) | Downstream (blocks signal reception) |
| Molecular Target | δ-Opioid receptors → Calcium channels | Nicotinic acetylcholine receptors (nAChRs) |
| Inspiration | Natural enkephalin peptides | Temple Viper waglerin-1 toxin |
| Amino Acids | 5 (pentapeptide) | 3 (tripeptide) |
| Sequence | Tyr-D-Ala-Gly-Phe-Leu | Dipeptide diaminobutyroyl benzylamide diacetate |
| INCI Name | Pentapeptide-18 | Dipeptide Diaminobutyroyl Benzylamide Diacetate |
| Developer | Lipotec (Lubrizol) | Pentapharm (DSM) |
| Primary Evidence | ~25% synergy enhancement with SNARE peptides | 52% forehead wrinkle reduction (28 days) |
| Typical Concentration | 3-8% | 1-4% |
| Commercial Since | Mid-2000s | 2006 |
Upstream Enkephalin vs Downstream Receptor Blocking
Neuromuscular Signalling Pathways
┌─────────────────────────────────────────────────────────────────────────────────┐ │ NEUROMUSCULAR SIGNALLING: TWO DISTINCT INTERVENTION POINTS │ │ │ │ ┌─────────────────────────────────────────────────────────────────────────┐ │ │ │ PRE-SYNAPTIC (NERVE TERMINAL) │ │ │ │ │ │ │ │ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐ │ │ │ │ │ δ-OPIOID │ │ CALCIUM │ │ SNARE │ │ │ │ │ │ RECEPTORS │───────▶│ CHANNELS │───────▶│ COMPLEX │ │ │ │ │ │ │ │ │ │ │ │ │ │ │ └──────────────┘ └──────────────┘ └──────────────┘ │ │ │ │ ▲ │ │ │ │ │ │ ▼ │ │ │ │ ┌──────┴──────┐ ┌──────────────┐ │ │ │ │ │ LEUPHASYL │ │ ACETYLCHOLINE│ │ │ │ │ │ ACTIVATES │ │ RELEASE │ │ │ │ │ │ (UPSTREAM) │ │ │ │ │ │ │ └─────────────┘ └───────┬──────┘ │ │ │ └─────────────────────────────────────────────────────────┼───────────────┘ │ │ │ │ │ ════════════════════════ SYNAPTIC CLEFT ═════════════════════════════════════ │ │ │ │ │ ┌─────────────────────────────────────────────────────────┼───────────────┐ │ │ │ POST-SYNAPTIC (MUSCLE CELL) ▼ │ │ │ │ │ │ │ │ ┌──────────────┐ ┌──────────────┐ │ │ │ │ │ NICOTINIC │ │ MUSCLE │ │ │ │ │ │ RECEPTORS │───────▶│ CONTRACTION │ │ │ │ │ │ (nAChRs) │ │ │ │ │ │ │ └──────────────┘ └──────────────┘ │ │ │ │ ▲ │ │ │ │ │ │ │ │ │ ┌──────┴──────┐ │ │ │ │ │ SYN-AKE │ │ │ │ │ │ BLOCKS │ │ │ │ │ │(DOWNSTREAM) │ │ │ │ │ └─────────────┘ │ │ │ └─────────────────────────────────────────────────────────────────────────┘ │ │ │ │ ═══════════════════════════════════════════════════════════════════════════ │ │ │ │ LEUPHASYL (Upstream): SYN-AKE (Downstream): │ │ ───────────────────── ───────────────────── │ │ • Activates δ-opioid receptors • Competes for nAChR binding sites │ │ • Reduces Ca²⁺ channel activity • Blocks acetylcholine reception │ │ • ↓ Vesicle release probability • Prevents muscle depolarisation │ │ • Less neurotransmitter released • ↓ Contraction even if ACh released │ │ │ │ RESULT: Nerve sends weaker signal RESULT: Muscle ignores the signal │ │ │ │ COMBINED: Multi-pathway modulation from both sides of the synapse │ └─────────────────────────────────────────────────────────────────────────────────┘
Leuphasyl
Leuphasyl: The Enkephalin Pathway Modulator
Leuphasyl (Pentapeptide-18) works through one of the body's own regulatory systems—the enkephalin (opioid) pathway. Its sequence (Tyr-D-Ala-Gly-Phe-Leu) mimics natural enkephalin peptides that modulate neurotransmission.
Mechanism of Action:
1. **δ-Opioid Receptor Activation:** Leuphasyl binds to δ-opioid receptors located on peripheral nerve terminals in the skin 2. **G-Protein Signalling Cascade:** Receptor activation triggers intracellular signalling that modulates ion channel activity 3. **Calcium Channel Modulation:** Reduces the activity of voltage-gated calcium channels 4. **Decreased Calcium Influx:** Less calcium enters the nerve terminal during depolarisation 5. **Reduced Vesicle Fusion:** Lower calcium levels mean fewer acetylcholine-containing vesicles fuse with the membrane 6. **Weaker Signal Output:** The nerve releases less neurotransmitter per action potential
Key Characteristics:
- **Upstream Position:** Works at the earliest stage of neuromuscular signalling—before calcium influx triggers vesicle release - **Signal Attenuation:** Reduces the STRENGTH of signals rather than blocking transmission entirely - **Synergy-Oriented:** Designed specifically to enhance other peptides by adding an independent pathway - **Local Action Only:** Works on peripheral nerve terminals—cannot produce central opioid effects (no systemic pain relief, sedation, or dependence)
Clinical Evidence: Studies demonstrate ~25% enhanced efficacy when combined with SNARE-targeting peptides. A calcium channel modulation assessment showed 35% reduction in calcium influx through voltage-gated channels.
Syn-Ake
Syn-Ake: The Receptor Antagonist
Syn-Ake is a tripeptide designed to mimic waglerin-1, a component of Temple Viper (Tropidolaemus wagleri) venom. Unlike the dangerous full toxin, Syn-Ake's simplified structure provides cosmetic benefits without safety concerns.
Mechanism of Action:
1. **nAChR Competition:** Syn-Ake binds to nicotinic acetylcholine receptors on muscle cell membranes 2. **Competitive Antagonism:** Occupies receptor binding sites, preventing acetylcholine from activating them 3. **Signal Reception Blocked:** Even when acetylcholine is released normally, the muscle receives a weaker signal 4. **Reduced Depolarisation:** Less receptor activation means less sodium influx and reduced muscle depolarisation 5. **Softened Contraction:** Expression lines gradually soften as repetitive muscle contractions are attenuated
Key Characteristics:
- **Downstream Position:** Works at the final stage—after neurotransmitter release, at the point of muscle activation - **Receptor-Level Blocking:** Targets the receiving end rather than the sending end of neuromuscular signalling - **Independent of SNARE:** Completely different mechanism from Argireline/SNAP-8, enabling genuine combination therapy - **Venom-Inspired Safety:** Highly modified from natural toxin—safe for topical cosmetic use
Clinical Evidence: The Pentapharm forehead study demonstrated 52% reduction in forehead wrinkle depth at 28 days. A Swiss clinical trial (2013) showed 82% volunteer satisfaction rate. Electromyography studies confirmed reduced muscle contraction frequency.
Clinical Trial Evidence
Leuphasyl Clinical Studies
Participants: 40 women aged 35-60
Duration: 28 days
~25% enhanced wrinkle reduction when Leuphasyl combined with Argireline vs Argireline alone
Primary evidence for dual-pathway synergy; validated enhancer positioning
Participants: In vitro δ-opioid receptor study
Duration: Acute exposure
Confirmed selective binding to δ-opioid receptors; dose-dependent calcium modulation
Validated enkephalin-mimetic mechanism distinct from other pathways
Participants: 32 subjects
Duration: 28 days
Leuphasyl + Argireline: 38% crow's feet reduction vs 28% for Argireline alone
Quantified synergistic benefit in sensitive periorbital area
Participants: In vitro neuronal cell model
Duration: Acute exposure
35% reduction in calcium influx through voltage-gated channels
Confirmed upstream mechanism—signal attenuation before vesicle release
Syn-Ake Clinical Studies
Participants: 45 women aged 40-60
Duration: 28 days
52% reduction in forehead wrinkle depth with 4% Syn-Ake
Landmark efficacy data; established receptor antagonism as viable cosmetic mechanism
Participants: 60 volunteers
Duration: 56 days
82% volunteer satisfaction rate; 63% visible wrinkle improvement
Long-term efficacy and consumer perception validation
Participants: 24 subjects
Duration: 28 days
Significant reduction in frontalis muscle contraction frequency
Objective demonstration of neuromuscular modulation
Participants: In vitro receptor binding study
Duration: Acute exposure
Confirmed competitive binding to nicotinic acetylcholine receptor α-subunits
Validated waglerin-mimetic mechanism at molecular level
Benefits Comparison
Leuphasyl Unique Benefits
- Works through unique enkephalin pathway (different from all other cosmetic peptides)
- Reduces the upstream calcium signals that trigger neurotransmitter release
- Enhances Argireline/SNAP-8 efficacy by ~25% when combined
- Creates genuine synergy through mechanistically independent pathway
- Excellent tolerability with no systemic opioid effects
- D-Alanine modification provides enhanced enzymatic stability
- Suitable for all skin types including sensitive
- Designed specifically as an enhancer for multi-peptide protocols
Shared Benefits
- Both target neuromuscular signalling to reduce expression lines
- Both work through completely independent mechanisms enabling combination
- Both are approved cosmetic ingredients globally
- Both have excellent safety profiles with rare side effects
- Both are reversible and safe for home use
- Both work best with consistent twice-daily application
- Both are compatible with SNARE peptides (Argireline/SNAP-8)
- Both provide gradual, natural-looking results
Syn-Ake Unique Benefits
- Strongest standalone efficacy data among neuromuscular peptides (52% reduction)
- Works at the post-synaptic receptor level (unique mechanism)
- Venom-inspired science with proven safety profile
- Effective as standalone treatment or in combinations
- 82% consumer satisfaction rate in clinical trials
- Works at lower concentrations (1-4%) due to high receptor affinity
- Completely independent of SNARE pathway peptides
- Safe for home use without medical supervision
Research & Evidence
Leuphasyl Research
Leuphasyl Research Summary:
Leuphasyl research demonstrates its unique position as an enkephalin pathway modulator designed for synergistic combination use:
Synergy Studies (Lipotec/Lubrizol): Clinical evaluation showed approximately 25% enhanced wrinkle reduction when Leuphasyl was combined with Argireline versus Argireline alone. This validates the dual-pathway hypothesis.
Enkephalin Receptor Binding: In vitro studies confirmed selective binding to δ-opioid receptors and dose-dependent calcium channel modulation, validating the mechanism as distinct from SNARE peptides.
Periorbital Studies: Clinical trials showed 38% crow's feet reduction with Leuphasyl + Argireline versus 28% for Argireline alone—a 35% enhancement.
Calcium Channel Modulation: Neuronal cell studies demonstrated 35% reduction in calcium influx through voltage-gated channels, confirming the upstream signal attenuation mechanism.
Syn-Ake Research
Syn-Ake Research Summary:
Syn-Ake has robust standalone efficacy data demonstrating receptor antagonism as a viable cosmetic mechanism:
Pentapharm Forehead Study (2006): Landmark study showing 52% reduction in forehead wrinkle depth at 28 days with 4% Syn-Ake—the strongest standalone efficacy among cosmetic neuromuscular peptides.
Swiss Multi-Centre Trial (2013): 60 volunteers over 56 days: 82% satisfaction rate and 63% visible wrinkle improvement. Validates both efficacy and consumer acceptance.
Electromyography Study (2008): Objective demonstration of reduced frontalis muscle contraction frequency, confirming the neuromuscular mechanism beyond visual assessment.
Receptor Competition Assay: In vitro confirmation of competitive binding to nicotinic acetylcholine receptor α-subunits, validating the waglerin-mimetic mechanism.
Head-to-Head Analysis
Leuphasyl vs Syn-Ake: Position Comparison
These peptides work at opposite ends of the neuromuscular junction:
| Aspect | Leuphasyl | Syn-Ake | |--------|-----------|---------| | Position | Pre-synaptic (nerve) | Post-synaptic (muscle) | | Pathway | Enkephalin/δ-opioid | Nicotinic receptor | | Target | Calcium channels | nAChRs | | Result | Less signal sent | Signal ignored | | Evidence Type | Synergy data | Standalone efficacy |
Why They're Complementary: These peptides modulate signalling from both sides of the synapse: 1. Leuphasyl reduces what the nerve SENDS 2. Syn-Ake blocks what the muscle RECEIVES 3. Combined: Dual-sided neuromuscular modulation
Best Practice: Use BOTH peptides together with Argireline for triple-pathway expression line treatment.
Protocol Comparison
Leuphasyl Protocol
Leuphasyl Usage Protocol:
Concentration: 3-8% in topical formulations Frequency: Twice daily (morning and evening) Duration: Visible effects within 2-4 weeks; optimal results at 8+ weeks Application Areas: Expression-prone zones (forehead, crow's feet, frown lines)
Key Consideration: Leuphasyl is designed as an ENHANCER for other neuromuscular peptides. While it works independently, optimal results come from combination use with Argireline or SNAP-8.
Combination Strategy: Look for products containing Pentapeptide-18 (Leuphasyl) alongside SNARE peptides and/or Syn-Ake for multi-pathway benefits.
Syn-Ake Protocol
Syn-Ake Usage Protocol:
Concentration: 1-4% in topical formulations (effective at lower concentrations) Frequency: Twice daily (morning and evening) Duration: Visible softening within 2-4 weeks; continued improvement over 8+ weeks Application Areas: Expression lines (forehead, crow's feet, frown lines, lip lines)
Key Consideration: Syn-Ake is effective as a standalone treatment but works even better when combined with other neuromuscular peptides for multi-pathway modulation.
Application Order: 1. Cleanse and tone 2. Apply Syn-Ake serum 3. Follow with moisturiser and sunscreen (AM)
Combined Use
Optimal Combination: Leuphasyl + Syn-Ake + Argireline
Triple-Pathway Strategy: Combining all three peptides creates maximum neuromuscular modulation:
1. Argireline (5-10%): Blocks SNARE complex (vesicle fusion) 2. Leuphasyl (3-8%): Reduces calcium signals (release probability) 3. Syn-Ake (1-4%): Blocks nicotinic receptors (signal reception)
Product Selection: Option 1: Multi-peptide serum containing all three Option 2: Layer separate serums (apply in any order)
Full Anti-Ageing Stack: Add collagen-stimulating peptides for comprehensive results: - Neuromuscular: Argireline + Leuphasyl + Syn-Ake - Collagen: Matrixyl or GHK-Cu - Regeneration: GHK-Cu for gene modulation
Timeline: - Week 2-4: Initial softening of expression lines - Week 8+: Optimal cumulative results
Safety Profiles
Leuphasyl Safety
Leuphasyl Safety Profile:
Excellent Tolerability: - Very well tolerated across all skin types - No systemic opioid effects despite enkephalin mechanism - Works locally on peripheral nerve terminals only - Cannot cross blood-brain barrier
Reported Effects (Rare): - Mild irritation (uncommon) - Temporary redness (rare) - Slight tingling (occasional)
Regulatory Status: - Approved cosmetic ingredient (UK, EU, USA, global) - INCI: Pentapeptide-18 - No concentration restrictions
Syn-Ake Safety
Syn-Ake Safety Profile:
Established Safety Record: - Commercial use since 2006 (18+ years) - Simplified tripeptide—not actual venom - Safe for home use without medical supervision
Reported Effects (Rare): - Mild irritation (uncommon) - Temporary redness (rare) - Slight tingling (occasional)
Mechanism Safety: - Competitive receptor binding (reversible) - Cannot cause paralysis or drooping - Effects are subtle and localised
Regulatory Status: - Approved cosmetic ingredient globally - INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate
The Verdict: When to Choose Which?
Choose Leuphasyl When:
- Building a multi-peptide expression line protocol
- Already using Argireline and want to enhance results
- Looking for upstream signal modulation
- Want unique enkephalin pathway coverage
- Creating comprehensive triple-pathway stacks
Choose Syn-Ake When:
- Want standalone neuromuscular treatment with proven efficacy
- Looking for the strongest single-peptide efficacy data
- Prefer receptor-level blocking mechanism
- Want venom-inspired science with safety assurance
- Building post-synaptic component of multi-peptide protocol
Consider Combining When:
- RECOMMENDED—these peptides are designed for complementary use
- Maximum expression line treatment through dual-sided modulation
- Building comprehensive anti-ageing protocols
- Adding to existing SNARE peptide routines for triple-pathway coverage
- Want both upstream signal reduction AND downstream receptor blocking
Frequently Asked Questions
Conclusion
Leuphasyl and Syn-Ake represent two of the most mechanistically distinct neuromuscular peptides available—positioned at opposite ends of the signalling cascade with zero overlap.
Understanding the Mechanisms: - Leuphasyl (Upstream/Pre-synaptic): Activates enkephalin receptors → reduces calcium channel activity → less neurotransmitter released - Syn-Ake (Downstream/Post-synaptic): Blocks nicotinic receptors → prevents acetylcholine reception → muscle ignores the signal
The Strategic Insight: These peptides aren't competitors—they're complementary partners. Leuphasyl reduces what the nerve SENDS; Syn-Ake blocks what the muscle RECEIVES. Combined, they create dual-sided modulation of the neuromuscular junction.
Optimal Protocol: For maximum expression line treatment, combine both Leuphasyl and Syn-Ake with SNARE-targeting peptides (Argireline or SNAP-8) to create a triple or quad-pathway stack:
1. Argireline/SNAP-8: Blocks SNARE complex (vesicle fusion) 2. Leuphasyl: Reduces calcium signalling (release probability) 3. Syn-Ake: Blocks nicotinic receptors (signal reception) 4. Optional Matrixyl: Stimulates collagen for static wrinkles
Key Takeaway: Rather than choosing between Leuphasyl and Syn-Ake, recognise them as essential partners in comprehensive anti-ageing protocols. Their independent mechanisms enable genuine synergy that single-peptide approaches cannot achieve.
For research sourcing and further information: Peptide Barn UK
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Leuphasyl nor Syn-Ake is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.